Evaluation of sexual hormones in premenopausal women with breast cancer in different stage, and its correlation with age and dosage of radiation therapy

Abstract

Breast cancer is the most common malignant tumor could be leads a death among females worldwide. It is Hormone-dependent cancer especially sex hormones. There were many studies about the sex hormones levels in the postmenopausal women with breast cancer but about in premenopausal is very rare. So The aim of this work was to study the different in concentrations of sexual hormones in premenopausal women and its different depend on the stage of cancer, and find its correlation with age and dosage of radiation therapy. This work included (30) Iraqi women with breast cancer and (20) healthy. Their ages were between 40 to 50 years. The stage of cancer, the number of radiation therapy dosage and the history of dieses are recorded from the profile of all patients. Blood samples were collected from all subjects. liteinizing hormone (LH), follicle stimulating hormone (FSH), Estrodiol ES, prolactin (Prol), testosterone (Testo) and progesterone (Prog). ES, FSH, LH and Testo hormones levels were significantly higher but Prog level was significantly lower in patient group while there was no significantly difference in Prol levels in patient and control groups. ES levels were significantly lower in patient in stage2 than those in stage3 while there was no significantly difference in all the rest hormones levels of patient in stage 2 and 3. It could be concluded that the breast cancer in premenopausal women may elevate the concentration of serum sex hormones except Prog which was reduced and Prol which hasn’t changed. Only ES level elevated depend on the development of breast cancer.

References

  • Althuis MD, Brogan DR, Coates RJ, Daling JR, Gammon MD, Malone KE, (2003) Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer. [Comparative Study Research Support, U.S. Gov’t, Non-P.H.S.]. 13;88(1):50-7. https://doi.org/10.1038/sj.bjc.6600691
  • Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. [Comparative Study Research Support, N.I.H., Extramural]. 10;26(20):3324-30. https://doi.org/10.1200/JCO.2007.14.2471
  • Anders CK, Johnson R, Litton J, Phillips M, Bleyer A, (2009) Breast cancer before age 40 years. Semin Oncol. [Review]. 36(3):237-49. https://doi.org/10.1053/j.seminoncol.2009.03.001
  • Bernstein L, Ross RK, (1993) Endogenous hormones and breast cancer risk. Epidemiol Rev. [Research Support, U.S. Gov’t, P.H.S. Review]. 15(1):48-65.
  • Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 13(2):273-9. https://doi.org/10.1093/annonc/mdf039
  • de Blok CJM, Wiepjes CM, Nota NM, van Engelen K, Adank MA, Dreijerink KMA, (2019) Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. Bmj. 14;365:l1652. https://doi.org/10.1136/bmj.l1652
  • Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F, (2017) Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. Lancet Oncol. [Research Support, Non-U.S. Gov’t]. 218(12):1579-89.
  • Gabriel CA, Domchek SM, (2010) Breast cancer in young women. Breast Cancer Res. [Review]. 12(5):212. https://doi.org/10.1186/bcr2647
  • Gharib SD, Wierman ME, Shupnik MA, Chin WW, (1990) Molecular biology of the pituitary gonadotropins. Endocr Rev. [Comparative Study Review]. 11(1):177-99.
  • Hall JE, Lavoie HB, Marsh EE, Martin KA, (2000) Decrease in gonadotropin-releasing hormone (GnRH) pulse frequency with aging in postmenopausal women. J Clin Endocrinol Metab. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. 85(5):1794-800. https://doi.org/10.1210/jc.85.5.1794
  • Hernandez L, Nunez-Villarl MJ, Martinez-Arribas F, Pollan M, Schneider J, (2005) Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors. Anticancer Res. 25(1B):451-4.
  • Jafarzadeh M, Mousavizadeh K, Joghataei MT, Hashemi Bahremani M, Safa M, Asghari SM. A (2018).Fibroblast Growth Factor Antagonist Peptide Inhibits Breast Cancer in BALB/c Mice , 13(1), 348-354 https://doi.org/10.1515/biol-2018-0043
  • Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. [Multicenter Study Research Support, Non-U.S. Gov’t]. 12(4):1071-82.
  • Key T, Appleby P, Barnes I, Reeves G, (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. [Meta-Analysis Research Support, Non-U.S. Gov’t]. 94(8):606-16. https://doi.org/10.1093/jnci/94.8.606
  • Key TJ, Verkasalo PK, Banks E, (2001) Epidemiology of breast cancer. Lancet Oncol. [Research Support, Non-U.S. Gov’t Review]. 2(3):133-40.
  • Koh J, Kim MJ, (2019) Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage. Korean J Radiol. [Research Support, Non-U.S. Gov’t]. 20(1):69-82. https://doi.org/10.3348/kjr.2018.0231
  • Kumar RR, Ganguly B, (2018) Quality of Life in Relation to Hormonal Therapy in Breast Cancer Patients- an Evidence Based Review. Ann Clin Toxicol. 1(1):1005.
  • Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE, (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. [Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S.]. 96(24):1856-65. https://doi.org/10.1093/jnci/djh336
  • Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, et al. (2017). Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 390(10100), 1151-1210. https://doi.org/10.1016/S0140-6736(17)32152-9
  • Onland-Moret NC, Kaaks R, van Noord PA, Rinaldi S, Key T, Grobbee DE, (2003) Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer. [Comparative Study Research Support, Non-U.S. Gov’t].;88(9):1394-9. https://doi.org/10.1038/sj.bjc.6600890
  • Sanchez AM, Flamini MI, Russo E, Casarosa E, Pacini S, Petrini M, (2016) LH and FSH promote migration and invasion properties of a breast cancer cell line through regulatory actions on the actin cytoskeleton. Mol Cell Endocrinol. [Research Support, Non-U.S. Gov’t]. 437:22-34.
  • Sanchez AM, Flamini MI, Zullino S, Russo E, Giannini A, Mannella P, (2018) Regulatory Actions of LH and Follicle-Stimulating Hormone on Breast Cancer Cells and Mammary Tumors in Rats. Front Endocrinol (Lausanne). 9:239. https://doi.org/10.3389/fendo.2018.00239
  • Sonnenblick EB, Shah AD, Goldstein Z, Reisman T, (2018) Breast Imaging of Transgender Individuals: A Review. Curr Radiol Rep. [Review]. 6(1):1.
  • Suba Z, (2016) Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery. Recent Pat Anticancer Drug Discov. [Review]. 11(3):254-66. https://doi.org/10.2174/1574892811666160415160211
  • Tracey MW, Joiner M, Kacin S, Burmeister J (2018) A Collaborative Educational Intervention Integrating Biology and Physics in Radiation Oncology: A Design Research Case Study. Contemporary Educational Technology, 9(2): 186-205. https://doi.org/10.30935/cet.414949
  • Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, et al. (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 390(10100), 1211-1259. https://doi.org/10.1016/S0140-6736(17)32154-2
  • Yager JD, Davidson NE, (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. 354(3):270-82. https://doi.org/10.1056/NEJMra050776
  • Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, (2004) Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer. [Research Support, U.S. Gov’t, P.H.S.]. 90(1):153-9. https://doi.org/10.1038/sj.bjc.6601517
  • Zhou J, Chen Y, Huang Y, Long J, Wan F, Zhang S, (2013) Serum follicle-stimulating hormone level is associated with human epidermal growth factor receptor type 2 and Ki67 expression in post-menopausal females with breast cancer. Oncol Lett. 6(4):1128-32. https://doi.org/10.3892/ol.2013.1516

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.